LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its product portfolio consists of the LENSAR Laser System and ALLY Adaptive Cataract Treatment System (ALLY System) and its associated consumable components. The system incorporates a range of technologies designed to assist the surgeon in obtaining visual outcomes. The consumable portion of the system consists of a disposable patient interface device kit. The ALLY System is designed to combine its femtosecond laser technology features with enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room or in-office surgical suite. Its system is used across surgeons, hospital outpatient surgical facilities and ambulatory surgery centers.
BörsenkürzelLNSR
Name des UnternehmensLENSAR Inc
IPO-datumSep 21, 2020
CEOMr. Nicholas T. (Nick) Curtis
Anzahl der mitarbeiter140
WertpapierartOrdinary Share
GeschäftsjahresendeSep 21
Addresse2800 Discovery Drive
StadtORLANDO
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl32826
Telefon18885367271
Websitehttps://www.lensar.com/
BörsenkürzelLNSR
IPO-datumSep 21, 2020
CEOMr. Nicholas T. (Nick) Curtis
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten